Persistence of Acetamiprid in/on Mustard (Brassica juncea L.)

S. Pramanik,J. Bhattacharyya,Surajit Dutta,P. Dey,Anusuya Bhattacharyya

DOI: https://doi.org/10.1007/S00128-006-0929-7

2006-02-01

Bulletin of Environmental Contamination and Toxicology

Abstract:

What problem does this paper attempt to address?

Downstaging treatment for patients with hepatocelluar carcinoma before transplantation

Guangjiang Jiang,Sunbin Ling,Qifan Zhan,Li Zhuang,Xiao Xu

DOI: https://doi.org/10.1016/j.trre.2021.100606

2021-01-01

Abstract:Liver transplantation (LT), one of the radical methods of treating liver cancer, has brought new hope for the treatment of unresectable liver cancer. Currently, patients who meet transplant criteria can achieve a favorable prognosis, but those who exceed transplant criteria tend not to have very satisfactory outcomes. For patients whose tumor burden exceeds the transplant criteria, downstaging treatment is a promising method to reduce tumor burden to within the transplant criteria that may lead to good posttransplant survival. Multiple treatments, such as transcatheter arterial chemoembolization (TACE), transarterial radioembolization (TARE), percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA), have been used as downstaging treatments. However, there are still some issues that limit the effectiveness of downstaging treatments, such as the inclusion criteria for downstaging, which the choice of downstaging treatment method, and the endpoint of downstaging, all of which are worthy of further discussion. Based on the published literature, this review discusses these issues. (c) 2021 Elsevier Inc. All rights reserved.
Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?

Hirak Pahari,Javid A Peer,Shikhar Tripathi,Suresh K Singhvi,Ushast Dhir

DOI: https://doi.org/10.4292/wjgpt.v15.i5.97570

2024-09-05

World Journal of Gastrointestinal Pharmacology and Therapeutics

Abstract:Liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) and chronic liver disease (CLD) is limited by factors such as tumor size, number, portal venous or hepatic venous invasion and extrahepatic disease. Although previously established criteria, such as Milan or UCSF, have been relaxed globally to accommodate more potential recipients with comparable 5-year outcomes, there is still a subset of the population that has advanced HCC with or without portal vein tumor thrombosis without detectable extrahepatic spread who do not qualify or are unable to be downstaged by conventional methods and do not qualify for liver transplantation. Immune checkpoint inhibitors (ICI) such as atezolizumab, pembrolizumab, or nivolumab have given hope to this group of patients. We completed a comprehensive literature review using PubMed, Google Scholar, reference citation analysis, and CrossRef. The search utilized keywords such as 'liver transplant', 'HCC', 'hepatocellular carcinoma', 'immune checkpoint inhibitors', 'ICI', 'atezolizumab', and 'nivolumab'. Several case reports have documented successful downstaging of HCC using the atezolizumab/bevacizumab combination prior to LT, with acceptable early outcomes comparable to other criteria. Adverse effects of ICI have also been reported during the perioperative period. In such cases, a 1.5-month interval between ICI therapy and LT has been suggested. Overall, the results of downstaging using combination immunotherapy were encouraging and promising. Early reports suggested a potential ray of hope for patients with CLD and advanced HCC, especially those with multifocal HCC or branch portal venous tumor thrombosis. However, prospective studies and further experience will reveal the optimal dosage, duration, and timing prior to LT and evaluate both short- and long-term outcomes in terms of rejection, infection, recurrence rates, and survival.
Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteria

R. Hirose,B. Hameed,Oren K. Fix,J. Dodge,J. Roberts,F. Yao,N. Fidelman,R. Kerlan,N. Mehta,J. Flemming

DOI: https://doi.org/10.1002/hep.27752

IF: 17.298

2015-06-01

Hepatology

Abstract:We report on the long‐term intention‐to‐treat (ITT) outcome of 118 patients with hepatocellular carcinoma (HCC) undergoing downstaging to within Milan/United Network for Organ Sharing T2 criteria before liver transplantation (LT) since 2002 and compare the results with 488 patients listed for LT with HCC meeting T2 criteria at listing in the same period. The downstaging subgroups include 1 lesion >5 and ≤8 cm (n = 43), 2 or 3 lesions at least one >3 and ≤5 cm with total tumor diameter ≤8 cm (n = 61), or 4‐5 lesions each ≤3 cm with total tumor diameter ≤8 cm (n = 14). In the downstaging group, 64 patients (54.2%) had received LT and 5 (7.5%) developed HCC recurrence. Two of the five patients with HCC recurrence had 4‐5 tumors at presentation. The 1‐ and 2‐year cumulative probabilities for dropout (competing risk) were 24.1% and 34.2% in the downstaging group versus 20.3% and 25.6% in the T2 group (P = 0.04). Kaplan‐Meier's 5‐year post‐transplant survival and recurrence‐free probabilities were 77.8% and 90.8%, respectively, in the downstaging group versus 81% and 88%, respectively, in the T2 group (P = 0.69 and P = 0.66, respectively). The 5‐year ITT survival was 56.1% in the downstaging group versus 63.3% in the T2 group (P = 0.29). Factors predicting dropout in the downstaging group included pretreatment alpha‐fetoprotein ≥1,000 ng/mL (multivariate hazard ratio [HR]: 2.42; P = 0.02) and Child's B versus Child's A cirrhosis (multivariate HR: 2.19; P = 0.04). Conclusion: Successful downstaging of HCC to within T2 criteria was associated with a low rate of HCC recurrence and excellent post‐transplant survival, comparable to those meeting T2 criteria without downstaging. Owing to the small number of patients with 4‐5 tumors, further investigations are needed to confirm the efficacy of downstaging in this subgroup. (Hepatology 2015;61:1968–1977)

Medicine
Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation

Nitin N. Katariya,Blanca C. Lizaola-Mayo,David M. Chascsa,Emmanouil Giorgakis,Bashar A. Aqel,Adyr A. Moss,Mitesh J. Borad,Amit K. Mathur,Pedro Luiz Serrano Uson Junior

DOI: https://doi.org/10.3390/cancers14092056

2022-04-19

Cancers

Abstract:Hepatocellular Carcinoma (HCC) is the most common liver malignancy and third leading cause of cancer death worldwide. For early- and intermediate-stage disease, liver-directed therapies for locoregional control, or down-staging prior to definitive surgical therapy with hepatic resection or liver transplantation, have been studied broadly, and are the mainstays of current treatment guidelines. As HCC incidence has continued to grow, and with more patients presenting with advanced disease, our current treatment modalities do not suffice, and better therapies are needed to improve disease-specific and overall survival. Until recently, sorafenib was the only systemic therapy utilized, and was associated with dismal results. The advent of immuno-oncology has been of significant interest, and has changed the paradigm of therapy for HCC. Lately, combination regimens including atezolizumab plus bevacizumab; durvalumab plus tremelimumab; and pembrolizumab plus Lenvatinib have shown impressive responses of between 25–35%; this is much higher than responses observed with single agents. Complete responses with checkpoint inhibitor therapy have been observed in advanced-stage HCC patients. These dramatic results have naturally led to several questions. Can or should checkpoint inhibitors, or other immunotherapy combinations, be used routinely before resection or transplant? Is there a synergistic effect of immunotherapy with locoregional therapy, and will pre-treatment increase disease-free survival after surgical intervention? Is it immunologically safe to use these therapies prior to transplantation? Much is still to be learned in terms of the dosing, timing, and overall utility of the use of immune checkpoint inhibitors for pre-transplant care and down-staging. More studies will be needed to understand the management of adverse events while maximizing the therapeutic window of these agents. In this review, we look at the current data on therapy with immune checkpoint inhibitors in advanced HCC, with a focus on pre-transplant treatment prior to liver transplant.

oncology
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

Xiao-Dong Zhu,Cheng Huang,Ying-Hao Shen,Yuan Ji,Ning-Ling Ge,Xu-Dong Qu,Lingli Chen,Wen-Kai Shi,Mei-Ling Li,Jin-Jin Zhu,Chang-Jun Tan,Zhao-You Tang,Jian Zhou,Jia Fan,Hui-Chuan Sun

DOI: https://doi.org/10.1159/000514313

2021-01-01

Liver Cancer

Abstract:Background: Combined therapy with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies has shown high tumor response rates for patients with unresectable hepatocellular carcinoma (HCC). However, using this treatment strategy to convert initially unresectable HCC to resectable HCC was not reported. Methods: Consecutive patients with unresectable HCC who received first-line therapy with combined TKI/anti-PD-1 antibodies were analyzed. Tumor response and resectability were evaluated via imaging every 2 months (±2 weeks) using RECIST v1.1. Resectability criteria were (1) R0 resection could be achieved with sufficient remnant liver volume and function; (2) intrahepatic lesions were evaluated as partial responses or stable disease for at least 2 months; (3) no severe or persistent adverse effects occurred; and (4) hepatectomy was not contraindicated. Results: Sixty-three consecutive patients were enrolled. Of them, 10 (15.9%) underwent R0 resection in 3.2 months (range: 2.4–8.3 months) after the initiation of combination therapy. At baseline, these 10 patients had a median largest tumor diameter of 9.3 cm, 7 had Barcelona Clinic Liver Cancer stage C (vascular invasion) disease, 2 had stage B, and 1 had stage A. Before surgery, 6 patients were evaluated as a partial response, 3 stable disease, and 1 partial response in the intrahepatic lesion but a new metastatic lesion in the right adrenal gland. Six patients (60%) achieved a pathological complete response. One patient died from immune-related adverse effects 2.4 months after hepatectomy. After a median follow-up of 11.2 months (range: 7.8–15.9 months) for other 9 patients, 8 survived without disease recurrence, and 1 experienced tumor recurrence. Conclusions: Combination of TKI/anti-PD-1 antibodies is a feasible conversion therapy for patients with unresectable HCC to become resectable. This study represents the largest patient cohort on downstaging role of combinational systemic therapy on TKI and PD-1 antibody for HCC.
Results of hepatocellular carcinoma downstaging through hepatic transarterial chemoembolization in liver transplantation

Beatriz G de Morais,Alex F Horbe,Gabriela Perdomo Coral,Raquel de F Jotz,Priscila C Fontana,Angelo A Mattos

DOI: https://doi.org/10.1097/MEG.0000000000002869

2025-01-01

Abstract:Introduction and aim: Liver transplantation plays an important role in treating hepatocellular carcinoma (HCC). However, diagnosis often occurs when the tumor size exceeds Milan criteria. In this context, locoregional treatments are frequently indicated. The aim of this study is to evaluate cirrhotic patients with HCC undergoing transarterial chemoembolization (TACE) for downstaging. Methods: This retrospective study assessed medical records of patients aged 18 years or older, diagnosed with HCC, who underwent TACE with the aim of downstaging. In the survival analysis, the Kaplan-Meier method was used. P -value <0.05 was considered statistically significant. Results: One hundred and twenty-three patients were evaluated, of which 44.7% underwent liver transplantation after downstaging. Mortality in these patients was 32.7% and the probability of survival at 1, 2, and 5 years after liver transplantation was, respectively, 80%, 70.8%, and 57%. When comparing with the unsuccessful group, there was a significant difference regarding number of nodules, size of the largest nodule, and response by Modified Response Evaluation Criteria in Solid Tumor. The characteristics of the group undergoing TACE for downstaging and the group undergoing TACE as a bridge to transplantation were also compared, and patients were selected through the propensity score. A more significant number of nodules was observed in patients who underwent downstaging ( P = 0.014) and they exceeded Milan criteria in the explanted liver more frequently ( P = 0.007). Survival in the downstaging group and in the bridge group was not different ( P = 0.342). Conclusion: Liver transplantation in patients with HCC after successful downstaging proved to be effective, as patients had adequate survival.
Pre-transplant Use of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Multicenter, Retrospective Cohort Study

Zhiyong Guo,Yao Liu,Qi Ling,Leibo Xu,Tielong Wang,Jiaxing Zhu,Yimou Lin,Xinjun Lu,Wei Qu,Fan Zhang,Zhijun Zhu,Jian Zhang,Zehua Jia,Ping Zeng,Wenjing Wang,Qiang Sun,Qijie Luo,Zemin Hu,Zhouying Zheng,Yingbin Jia,Jian Li,Yujian Zheng,Mengchao Wang,Shaoping Wang,Zemin Han,Sheng Yu,Chuanjiang Li,Shuhua Zhang,Jun Xiong,Feiwen Deng,Ying Liu,Huanwei Chen,Yanfeng Wang,Ling Li,Wenjin Liang,Andrea Schlegel,Bjorn Nashan,Chao Liu,Shusen Zheng,Xiaoshun He

DOI: https://doi.org/10.1016/j.ajt.2024.04.007

IF: 9.369

2024-01-01

American Journal of Transplantation

Abstract:Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in hepatocellular carcinoma patients are rapidly increasing. However, the evidence about the feasibility and safety of pre-LT ICI therapy is limited and controversial. To this end, a multicenter, retrospective cohort study was conducted in 11 Chinese centers. The results showed that 83 recipients received pre-LT ICI therapy during the study period. The median post-LT follow-up was 8.1 (interquartile range 3.3-14.6) months. During the short follow-up, 23 (27.7%) recipients developed allograft rejection, and 7 of them (30.4%) were diagnosed by liver biopsy. Multivariate logistics regression analysis showed that the time interval between the last administration of ICI therapy and LT (TLAT) ≥ 30 days was an independent protective factor for allograft rejection (odds ratio = 0.096, 95% confidence interval 0.026-0.357; P < .001). Multivariate Cox analysis showed that allograft rejection was an independent risk factor for overall survival (hazard ratio = 9.960, 95% confidence interval 1.006-98.610; P = .043). We conclude that patients who receive a pre-LT ICI therapy with a TLAT shorter than 30 days have a much higher risk of allograft rejection than those with a TLAT longer than 30 days. The presence of rejection episodes might be associated with higher post-LT mortality.
Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Wei-Chen Zhang,Ke-Yi Du,Song-Feng Yu,Xue-E Guo,Han-Xi Yu,Dong-Yan Wu,Cheng Pan,Cheng Zhang,Jian Wu,Li-Fang Bian,Lin-Ping Cao,Jun Yu

DOI: https://doi.org/10.1016/j.hbpd.2024.11.004

2024-01-01

Abstract:Background Transarterial chemoembolization (TACE) based neoadjuvant therapy was proven effective in hepatocellular carcinoma (HCC). Recently, tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) also showed promise in HCC treatment. However, the prognostic benefits associated with these treatments remain uncertain. This study aimed to explore the relationship between pathologic response and prognostic features in HCC patients who received neoadjuvant therapy. Methods HCC patients who received TACE either with or without TKIs/ICIs as neoadjuvant therapy before liver resection were retrospectively collected from the First Affiliated Hospital, Zhejiang University School of Medicine in China. Pathologic response was determined by calculating the proportion of non-viable area within the tumor. Major pathologic response (MPR) was defined as the presence of non-viable tumor cells reaching a minimum of 90%. Complete pathologic response (CPR) was characterized by the absence of viable cells observed in the tumor. Results A total of 481 patients meeting the inclusion criteria were enrolled, with 76 patients (15.8%) achieving CPR and 179 (37.2%) reaching MPR. The median recurrence-free survival (mRFS) in the CPR + MPR group was significantly higher than the non-MPR group (31.3 vs. 25.1 months). The difference in 3-year overall survival (OS) rate was insignificant (90.2% vs. 87.6%). Multivariate Cox regression analysis identified failure to achieve MPR (hazard ratio = 1.548, 95% confidence interval: 1.122-2.134; P = 0.008), HBsAg positivity (HR = 1.818, 95% CI: 1.062-3.115, P = 0.030), multiple lesions (HR = 2.278, 95% CI: 1.621-3.195, P < 0.001), and baseline tumor size > 5 cm (HR = 1.712, 95% CI: 1.031-2.849, P = 0.038) were independent risk factors for RFS. Subgroup analysis showed that 67 of 93 (72.0%) patients who received the combination of TACE, TKIs, and ICIs achieved MPR + CPR. Conclusions In individuals who received TACE-based neoadjuvant therapy for HCC, failure to achieve MPR emerges as an independent risk factor for RFS. Notably, the combination of TACE, TKIs, and ICIs demonstrated the highest rate of MPR.
Downstaging and laparoscopic hepatectomy plus intraoperative radiofrequency ablation for the treatment of initially unresectable multifocal hepatocellular carcinomas

Jianjun Wang,Hua Luo,Long Yi,Pei Yang,Xintao Zeng

DOI: https://doi.org/10.3389/fsurg.2023.1340657

IF: 1.8

2024-01-11

Frontiers in Surgery

Abstract:Background Using TKIs plus anti-PD-1 antibodies combined with TACE in the treatment of patients with initially unresectable multiple HCCs has a high tumour response rate, and using laparoscopic hepatectomy (LH) combined with intraoperative RFA for radical treatment of multiple HCCs after successful downstaging treatment has not been reported. Methods Consecutive patients with multiple HCCs (≤4 lesions) who were downstaged with TKIs plus anti-PD-1 antibodies combined with TACE were analysed. Imaging examinations were performed monthly, and RECIST v1.1 criteria were used to evaluate treatment effect and resectability. Results Forty-five consecutive patients with multiple HCCs who met the inclusion criteria received downstaging treatment with TKIs plus anti-PD-1 antibodies combined with TACE. Nine patients were successfully downstaged and met the R0 resection criteria, and 8 patients underwent surgery. Among the patients, 5 patients had BCLC stage C, and 3 patients had BCLC stage B. There were 2 lesions in 5 patients, 3 lesions in 2 patients, and 4 lesions in 1 patient. The average size of the main HCC was 8.5 cm (range: 5.4–9.1 cm), and the diameter of the remaining HCCs was 1.6 cm (range: 0.8–2.9 cm). The average time from the start of downstaging therapy to surgery was 81 days (range: 60–210 days). All 8 patients underwent LH of the main HCC, and the remaining HCCs were targeted with RFA. The mean operation time was 220 min (range 150–370 min), the average intraoperative blood loss was 260 ml (range 100–750 ml), there was no case conversion to laparotomy, and the average postoperative hospital stay was 9 days (range 7–25 days). The incidence of postoperative complications was 37.5% and there were no deaths. The average follow-up time was 18.2 months (range 6.1–22.4 months), 5 patients survived tumour-free, 2 patients had tumour recurrence, and 1 patient died. Conclusions After successful downstaging of multiple HCCs by treatment with TKIs plus anti-PD-1 antibodies and TACE, LH combined with RFA for radical surgery is safe and feasible, and the treatment effect is satisfactory. It is worthy of clinical reference, and its long-term effects require further research for confirmation.

surgery
Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study

Zhiyong Guo,Yao Liu,Qi Ling,Leibo Xu,Tielong Wang,Jiaxing Zhu,Yimou Lin,Xinjun Lu,Wei Qu,Fan Zhang,Zhijun Zhu,Jian Zhang,Zehua Jia,Ping Zeng,Wenjing Wang,Qiang Sun,Qijie Luo,Zemin Hu,Zhouying Zheng,Yingbin Jia,Jian Li,Yujian Zheng,Mengchao Wang,Shaoping Wang,Zemin Han,Sheng Yu,Chuanjiang Li,Shuhua Zhang,Jun Xiong,Feiwen Deng,Ying Liu,Huanwei Chen,Yanfeng Wang,Ling Li,Wenjin Liang,Andrea Schlegel,Björn Nashan,Chao Liu,Shusen Zheng,Xiaoshun He,Nashan Björn

DOI: https://doi.org/10.1016/j.ajt.2024.04.007

IF: 9.369

2024-04-01

American Journal of Transplantation

Abstract:Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in hepatocellular carcinoma patients are rapidly increasing. However, the evidence about the feasibility and safety of pre-LT ICI therapy is limited and controversial. To this end, a multicenter, retrospective cohort study was conducted in 11 Chinese centers. The results showed that 83 recipients received pre-LT ICI therapy during the study period. The median post-LT follow-up was 8.1 (interquartile range 3.3-14.6) months. During the short follow-up, 23 (27.7%) recipients developed allograft rejection, and 7 of them (30.4%) were diagnosed by liver biopsy. Multivariate logistics regression analysis showed that the time interval between the last administration of ICI therapy and LT (TLAT) ≥ 30 days was an independent protective factor for allograft rejection (odds ratio = 0.096, 95% confidence interval 0.026-0.357; P < .001). Multivariate Cox analysis showed that allograft rejection was an independent risk factor for overall survival (hazard ratio = 9.960, 95% confidence interval 1.006-98.610; P = .043). We conclude that patients who receive a pre-LT ICI therapy with a TLAT shorter than 30 days have a much higher risk of allograft rejection than those with a TLAT longer than 30 days. The presence of rejection episodes might be associated with higher post-LT mortality.

surgery,transplantation
Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria

Ani Kardashian,Sander S. Florman,Brandy Haydel,Richard M. Ruiz,Goran B. Klintmalm,David D. Lee,C. Burcin Taner,Federico Aucejo,Amit D. Tevar,Abhinav Humar,Elizabeth C. Verna,Karim J. Halazun,William C. Chapman,Neeta Vachharajani,Maarouf Hoteit,Matthew H. Levine,Mindie H. Nguyen,Marc L. Melcher,Alan N. Langnas,Carol A. Carney,Constance Mobley,Mark Ghobrial,Beth Amundsen,James F. Markmann,Debra L. Sudan,Christopher M. Jones,Jennifer Berumen,Alan W. Hemming,Johnny C. Hong,Joohyun Kim,Michael A. Zimmerman,Trevor L. Nydam,Abbas Rana,Michael L. Kueht,Thomas M. Fishbein,Daniela Markovic,Ronald W. Busuttil,Vatche G. Agopian

DOI: https://doi.org/10.1002/hep.31210

IF: 17.298

2020-12-01

Hepatology

Abstract:<p>The Organ Procurement and Transplantation Network recently approved liver transplant (LT) prioritization for patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are downstaged (DS) with locoregional therapy (LRT). We evaluated post‐LT outcomes, predictors of downstaging, and the impact of LRT in beyond‐MC HCC patients from the US Multicenter HCC Transplant Consortium (20 centers, 2002‐2013). Clinicopathologic characteristics, overall survival (OS), recurrence‐free survival (RFS), and HCC recurrence (HCC‐R) were compared between patients within MC (n=3,570) and beyond MC (n=789) who were downstaged (DS, n=465), treated with LRT and not downstaged (LRT‐NoDS, n=242), or untreated (NoLRT‐NoDS, n=82). Five‐year post‐LT OS and RFS was higher in MC (71.3% and 68.2%) compared to DS (64.3% and 59.5%), and lowest in NoDS (n=324; 60.2% and 53.8%; overall P<0.001). DS patients had superior RFS (60% vs 54%,P=0.043) and lower 5‐year HCC‐R (18% vs 32%,P<0.001) compared to NoDS, with further stratification by maximum radiologic tumor diameter (5‐year HCC‐R of 15.5% in DS/< 5cm and 39.1% in NoDS/>5cm,P<0.001). Multivariate predictors of downstaging included alpha‐fetoprotein response to LRT, pathologic tumor number and size, and wait time >12 months. LRT‐NoDS had greater HCC‐R compared to NoLRT‐NoDS (34.1% vs 26.1%,P<0.001), even after controlling for clinicopathologic variables (HR=2.33,P<0.001) and inverse probability of treatment weighted propensity matching (HR=1.82,P<0.001). <b>Conclusion</b> In LT recipients with HCC presenting beyond MC, successful downstaging is predicted by wait time, alpha‐fetoprotein response to LRT, and tumor burden, and results in excellent post‐LT outcomes, justifying expansion of LT criteria. In LRT‐NoDS patients, higher HCC‐R compared to NoLRT‐NoDS cannot be explained by clinicopathologic differences, suggesting a potentially aggravating role of LRT in patients with poor tumor biology that warrants further investigation.</p>

gastroenterology & hepatology
Liver-directed combined radiotherapy for downstaging beyond-Milan hepatocellular carcinoma to liver transplantation

Jina Kim,Yong Tae Kim,Jae Geun Lee,Dai Hoon Han,Dong Jin Joo,Do Young Kim,Jinsil Seong

DOI: https://doi.org/10.1016/j.ijrobp.2024.01.221

IF: 8.013

2024-02-16

International Journal of Radiation Oncology*Biology*Physics

Abstract:Background & Aims Curative surgery involving either resection or liver transplantation (LT) is indicated only for early stage hepatocellular carcinoma (HCC). Over the years, numerous efforts have been made to downstage advanced HCC to curative surgery using various locoregional therapies. In this study, we investigated the role of liver-directed combined radiotherapy (LD-CRT) as a downstaging strategy for converting beyond-Milan advanced HCC to LT. Approach From January 2009 to February 2022, 53 HCC patients who were initially beyond-Milan criteria were treated with LD-CRT and subsequent LT. These patients were compared to those who underwent upfront LT for within-Milan HCCs. The primary endpoint was overall survival (OS), and the secondary endpoint was recurrence-free survival (RFS). Results After LD-CRT, substantial downstaging was achieved in 35 (66 %) patients who were initially beyond-Milan to within-Milan. At a median follow-up period of 47.6 months (range, 6.9-151.7 months), 5-year OS and 2-year RFS of the patients who received downstaging LD-CRT followed by LT was 66.9% and 63.2%, respectively. Patients who were successfully downstaged to within-Milan following LD-CRT had improved 5-year OS compared with their counterparts (81.9% vs. 74.3%, p = 0.219). Recurrence after transplantation was observed in 18 patients (4 intrahepatic recurrences and 14 extrahepatic metastases). Conclusions Liver-directed combined radiotherapy achieved favorable oncological outcomes as a downstaging strategy for liver transplantation in patients with beyond-Milan HCC. This study suggests that the active adoption of liver-directed combined radiotherapy needs full consideration for patients with beyond-Milan HCC, opening a chance of curing patients with advanced HCC.

oncology,radiology, nuclear medicine & medical imaging
Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma

Maen Abdelrahim,Abdullah Esmail,Mukul K. Divatia,Jiaqiong Xu,Sudha Kodali,David W. Victor,Elizabeth Brombosz,Ashton A. Connor,Ashish Saharia,Ahmed Elaileh,Ahmed O. Kaseb,Rafik Mark Ghobrial

DOI: https://doi.org/10.3390/jcm13113068

IF: 3.9

2024-05-25

Journal of Clinical Medicine

Abstract:Background: Hepatocellular carcinoma (HCC) is widely recognized as the predominant type of primary liver malignancy. Orthotopic liver transplantation (OLT) has emerged as a highly effective treatment option for unresectable HCC. Immunotherapies as neoadjuvant options are now being actively investigated in the transplant oncology era to enhance outcomes in patients with HCC. Here, we report our experience with patients with HCC who had received Immune Checkpoint Inhibitors (ICPI) prior to curative OLT. Methods: This was a retrospective cohort that included patients with HCC who received ICPI prior to OLT at a single institution from January 2019 to August 2023. Graft rejection was assessed and reported along with the type of ICPI, malignancy treated, and the timing of ICPI in association with OLT. Results: During this cohort period, six patients with HCC underwent OLT after neoadjuvant ICPI. All patients were male with a median age of 61 (interquartile range: 59–64) years at OLT. Etiology associated with HCC was viral (N = 4) or Non-alcoholic steatohepatitis, NASH (N = 2). Tumor focality was multifocal (N = 4) and unifocal (N = 2). Lymphovascular invasion was identified in four patients. No perineural invasion was identified in any of the patients. All patients received ICPI including atezolizumab/bevacizumab (N = 4), nivolumab/ipilimumab (N = 1), and nivolumab as monotherapy (N = 1). All patients received either single or combined liver-directed/locoregional therapy, including transarterial chemoembolization (TACE), Yttrium-90 (Y90), stereotactic body radiotherapy (SBRT), and radiofrequency ablation (RFA). The median washout period was 5 months. All patients responded to ICPI and achieved a safe and successful OLT. All patients received tacrolimus plus mycophenolate as immunosuppressant (IS) therapy post-OLT and one patient received prednisone as additional IS. No patient had clinical evidence of rejection. Conclusions: This cohort emphasizes the success of tumor downstaging by ICPI for OLT when employed as the neoadjuvant therapy strategy. In addition, this study illustrated the importance of timing for the administration of ICPI before OLT. Given the lack of conclusive evidence in this therapeutic area, we believe that our study lays the groundwork for prospective trials to further examine the impact of ICPI prior to OLT.

medicine, general & internal
Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review

Zi-yun Qiao,Zi-jie Zhang,Zi-cheng Lv,Huan Tong,Zhi-feng Xi,Hao-xiang Wu,Xiao-song Chen,Lei Xia,Hao Feng,Jian-jun Zhang,Qiang Xia

DOI: https://doi.org/10.3389/fimmu.2021.653437

IF: 7.3

2021-07-19

Frontiers in Immunology

Abstract:Programmed cell death 1 (PD-1) blockade is considered contraindicated in liver transplant (LT) recipients due to potentially lethal consequences of graft rejection and loss. Though post-transplant PD-1 blockade had already been reported, pre-transplant use of PD-1 blockade has not been thoroughly investigated. This study explores the safety and efficacy of neoadjuvant PD-1 blockade in patients with hepatocellular carcinoma (HCC) after registration on the waiting list. Seven transplant recipients who underwent neoadjuvant PD-1 blockade combined with lenvatinib and subsequent LT were evaluated. The objective response rate (ORR) and disease control rate (DCR) was 71% and 85% according to the mRECIST criteria. Additionally, a literature review contained 29 patients were conducted to summarize the PD-1 blockade in LT for HCC. Twenty-two LT recipients used PD-1 inhibitors for recurrent HCC. 9.1% (2/22) and 4.5% (1/22) recipients achieved complete remission (CR) and partial remission (PR), respectively; 40.9% (9/22) recipients had progressive disease (PD). Allograft rejection occurred in 45% of patients. In total, seven patients from our center and three from the literature used pretransplant anti-PD-1 antibodies, eight patients (80%) had a PR, and the disease control rate was 100%. Biopsy-proven acute rejection (BPAR) incidence was 30% (3 in 10 patients), two patients died because of BPAR. This indicated that neoadjuvant PD-1-targeted immunotherapy plus tyrosine kinase inhibitors (TKI) exhibited promising efficacy with tolerable mortality in transplant recipients under close clinical monitoring.

immunology
Downstaging with atezolizumab-bevacizumab: a case series

Anand V Kulkarni,Parthasarathy Kumaraswamy,Balachandran Menon,Anuradha Sekaran,Anuhya Rambhatla,Sowmya Iyengar,Manasa Alla,Shantan Venishetty,Sumana Kolar Ramachandra,Giri V Premkumar,Mithun Sharma,P Nagaraja Rao,Duvvur Nageshwar Reddy,Amit G Singal

DOI: https://doi.org/10.17998/jlc.2024.05.12

Abstract:Backgrounds/aims: Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage unresectable HCC for liver transplantation (LT). Atezolizumab-bevacizumab (atezo-bev) can induce objective responses in nearly one-third of patients; however, the role and outcomes of downstaging using atezo-bev remains unknown. Methods: In this retrospective single-center study, we included consecutive patients between November 2020 and August 2023, who received atezo-bev with or without LRT and were subsequently considered for resection/LT after downstaging. Results: Of the 115 patients who received atezo-bev, 12 patients (10.4%) achieved complete or partial response and were willing to undergo LT; they (age, 58.5 years; women, 17%; Barcelona Clinic Liver Cancer stage system B/C, 5/7) had received 3-12 cycles of atezo- bev, and four of them had received prior LRT. Three patients died before LT, while three were awaiting LT. Six patients underwent curative therapies: four underwent living donor LT after a median of 79.5 days (range, 54-114) following the last atezo-bev dose, one underwent deceased donor LT 38 days after the last dose, and one underwent resection. All but one patient had complete pathologic response with no viable HCC. Three patients experienced wound healing complications, and one required re-exploration and succumbed to sepsis. After a median follow-up of 10 months (range, 4-30), none of the alive patients developed HCC recurrence or graft rejection. Conclusions: Surgical therapy, including LT, is possible after atezo-bev therapy in well-selected patients after downstaging.
Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation

Xinjun Lu,Qi Zhu,Junfeng Cai,Zuozhong Yang,Guangxiang Gu,Li Pang,Mingye Su,Fapeng Zhang,Haoming Lin,Wenrui Wu,Leibo Xu,Chao Liu

DOI: https://doi.org/10.1007/s00262-024-03853-9

IF: 6.63

2024-11-13

Cancer Immunology Immunotherapy

Abstract:Immune checkpoint inhibitor (ICI)-based immunotherapy has emerged as the most promising strategy for hepatocellular carcinoma (HCC) downstaging prior to liver transplantation (LT). However, further evidence is required to assess the feasibility and safety of pretransplant ICI exposure. We retrospective analyzed 159 HCC patients who underwent LT at our institution from June 2019 to December 2023, and 39 recipients (39/159, 24.5%) received pretransplant ICI therapy. The perioperative acute rejection rate and rejection-related mortality rate in the ICI group were 23.1% (9/39) and 12.8% (5/39), respectively, which were significantly higher than those in the non-ICI group, at 5% (6/120, P = 0.002) and 0% (0/120, P = 0.001). There was no significant difference in the 90-day post-transplant overall survival (OS) ( P = 0.447) and recurrence-free survival (RFS) ( P = 0.723) between these two groups. We found 37.1% (59/159) recipients were found to have microvascular invasion (MVI), no matter whether the HCC tumor is within Milan criteria or not. Notably, though MVI was identified as a risk factor for the LT recipients, pretransplant ICI exposure appeared to be a protective factor for HCC patients with MVI which benefits its overall survival. Besides, the RFS and OS in the ICI exposure recipients with MVI were comparable to the non-ICI exposure recipients without MVI. However, no synergistic anti-tumor effects were observed with pretransplant ICI immunotherapy when combined with locoregional of TACE, HAIC, RFA and systematic of lenvatinib or sorafenib downstaging treatments, nor with post-transplant adjuvant of systematic or FOLFOX chemotherapy. Further comprehensive studies are needed to balance the dual natural effects of immunotherapy by optimizing downstaging protocols and patient selection to reduce acute rejection and improve long-term survival.

oncology,immunology
TKIs treatment for HCC before Liver transplantation: an ELITA/ELTR collaborative study

C. Mazzarelli,S. Bhoori,S. Grandi,S Gruttadauria,I. Petridis,J.I. Herrero,F. Rotellar,A. Shcherba,C. den Hoed,W. Polak,D. Patrono,R. Romagnoli,A. Ottobrelli,M De Giorgio,A Loglio,S. Fagiouli,M. Colledan,O. Detry,J. Dewailde,P Toniutto,U. Baccarani,M.F. Donato,L. Caccamo,M. Vivarelli,G. Svegliati-Baroni,G. Conte,A. Dalbeni,D. Sarcedoti,A. Carraro,R. Viganò,G. Perricone,L. De Carlis,T.M. Manzia,G. Tisone,A. Grieco,A. Avolio,V. Mazzaferro,L.S. Belli

DOI: https://doi.org/10.1016/j.dld.2024.01.151

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Background and Aims Recent advances in systemic treatments for hepatocellular carcinoma (HCC) have driven the discussion on their possible role for downstaging advanced HCC prior to liver transplantation (LT) or for bridging to LT to prevent tumor progression and reduce the dropout risk. The aim of this study was to evaluate the outcome of patients treated with TKIs before LT. Method an online survey was sent to all centers affiliated to the ELITA/ELTR network between June and December 2022. Demographic and clinical data were retrospectively collected. Results Fifty-two patients, median age 60.5 years, receiving a LT between December 2006 and September 2022 were enrolled. Thirty patients (57.6%) were treated with TKI with a downstaging purpose, while 22 (42.3%) received TKI as a bridging treatment to LT. 34 patients (65%) received sorafenib, 15 lenvatinib (28%) and 3 patients (3%) a sequential therapy with sorafenib-regorafenib. Forty-eight patients (92%) received at least one locoregional treatment before LT. Only 12 patients (23%) were in Milan criteria at treatment start time. Twenty-nine patients were Milan-in at listing (55.7%). Nine patients had neoplastic portal vein thrombosis (17.3%). The five-year survival was 70% (Figure 1). After a median time of 7.7 months (5-12.7), 7 patients (13%) experienced HCC recurrence. The only factor associated with HCC recurrence was AFP (p 0.02) at LT-We observed only a single recurrence in one of the patients with neoplastic thrombosis. Twelve patients (23%) experienced vascular or early bleeding complications after LT. The type of TKIs or the time from the last dose to LT didn't influence the risk of post-LT complications. Conclusions This is the largest collected series of patients receiving TKIs pre-LT as downstaging/bridging therapy, with a very favourable long-term outcome (70 % at 5 years) even in patients with neoplastic vein thrombosis.

gastroenterology & hepatology
Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study

Parissa Tabrizian,Matthew Holzner,Veeral Ajmera,Amy K Kim,Kali Zhou,Gabriel T Schnickel,Kelly Torosian,Maarouf Hoteit,Rebecca Marino,Michael Li,Francis Yao,Sander S Florman,Myron E Schwartz,Neil Mehta

DOI: https://doi.org/10.1016/j.jhep.2024.09.003

2024-09-08

Abstract:Background and aims: The use of immune checkpoint inhibitors (ICI) in patients with advanced hepatocellular carcinoma (HCC) has become widespread with encouraging outcomes in the neoadjuvant setting. Safety and intention to treat (ITT) outcomes in the peri transplant setting are currently based on small and heterogenous single center reports. Methods: This first multiregional US study (2016-2023) included 117 consecutive HCC patients assessed for LT and treated preoperatively with ICIs. Intention to treat ITT and survival analyses were conducted with evaluation of post LT rejection rates. Results: In total, 86 (73.5%) patients exceeded MC and 65 (75.6%) were successfully downstaged (DS) within a median of 5.6 months. 43 (36.7%) underwent transplantation, including 18 (15.4%) within MC and 23 (19.7%) initially beyond and DS. Overall, 94% of the cohort received concurrent ICIs and locoregional therapies. No grade 4-5 adverse events occurred on the waiting list. The 3-year cumulative probability of dropout was 28% for those within MC and 48% for those beyond. Independent predictors of dropout included: being beyond MC (p<0.001), AFP doubling from baseline (p=0.014) and radiographic responses (p<0.001). The 3-year ITT survival was 71.1% (73.5% within MC vs 69.7% beyond MC, p=0.329), with 3-year post LT survival rate of 85%. Post-LT rejection occurred in 7 patients, six received their last dose of ICI less than 3 months prior to LT, resulting in one graft loss. Conclusions: The first multicenter evaluation of HCC patients receiving ICI pre-LT demonstrates favorable survival and safety outcomes, justifying continued utilization and further evaluation of this strategy in clinical practice. High tumor burden, doubling of AFP levels, and radiographic response were identified as predictors of unfavorable oncologic outcomes. Impact and implications: The first multicenter evaluation of pre-transplant immune-checkpoint-inhibitors in hepatocellular carcinoma to show promising intention-to-treat survival, safety and rejection rates. Immune-checkpoint-inhibitors, either alone or combined with LRT, demonstrate reliable efficacy. This preoperative strategy could be particularly beneficial for high-risk patients, including those requiring downstaging or with elevated AFP levels despite locoregional treatment. These findings fill current knowledge gaps and offer reassuring evidence for the feasibility of pre-transplant use of immune-checkpoint-inhibitors, pending results from ongoing trials.
Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

Li-Fu Kuo,Wen-Chun Liu,Ming-Feng Li,Fu-Huan Huang,Chu-Kuang Chou,Tsung-Hsien Chen,Yi-Tseng Tsai,Ping-I Hsu,Chao-Jen Li,I-Ting Wu,Kun-Feng Tsai

DOI: https://doi.org/10.1159/000542291

2024-10-28

Oncology

Abstract:Introduction: Patients with advanced-stage or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for transarterial chemoembolization (TACE) had poor prognoses. Recent advancements in hepatic arterial infusion chemotherapy (HAIC) and immune checkpoint inhibitors (ICIs) have demonstrated higher tumor response rates, which improved overall survival (OS). HAIC achieves an OS rate of approximately 14.5-15.3 months with a 39.1-42.5% tumor response rate. In comparison, ICIs have a 12-14 month OS rate with a 26-33% tumor response rate. Given these promising responses, this study evaluates the efficacy of conversion therapy with curative intent following HAIC or ICIs, focusing on survival outcomes. Methods: We retrospectively analyzed 80 patients with advanced or TACE-unsuitable intermediate HCC. Patients completed two HAIC or four ICI cycles, followed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria imaging. Based on demographics, cirrhosis status, Barcelona Clinic Liver Cancer classification (BCLC) stage, treatment responses, and treatment modality, survival impacts were analyzed. OS was compared between HAIC and immunotherapy groups. The effect of conversion therapy with curative intent on survival outcomes was analyzed using a Cox regression model. Results: Among the 80 patients, 26 achieved positive response (CR/PR) with HAIC or ICIs, and 9 of them subsequently underwent conversion therapy with curative intent. Key prognostic factors included Child-Pugh stage B versus A (HR = 2.21, p = 0.041), BCLC stage C versus B (HR = 4.38, p = 0.011), and elevated alpha-fetoprotein levels (HR = 5.02, p < 0.001). Positive responders saw substantial survival benefits (HR = 0.26, p = 0.001). Patients undergoing conversion therapy exhibited significantly enhanced survival. Median OS was 13.58 months with standard therapy, while the curative intent surgery group did not reach the median OS (p = 0.002). For CR/PR patients, 48-month survival was 75.0% for the curative surgery group versus 38.0% for standard treatment. Conclusion: Conversion therapy with curative intent following HAIC or ICIs might enhance survival in patients with advanced or TACE-unsuitable intermediate-stage HCC.
[Electroclinical correlations in 400 cases of photo-cardiozol activations].

H. Bonnet,J. Courjon

1951-06-01

Abstract:

Persistence of Acetamiprid in/on Mustard (Brassica juncea L.)

Downstaging treatment for patients with hepatocelluar carcinoma before transplantation

Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?

Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteria

Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

Results of hepatocellular carcinoma downstaging through hepatic transarterial chemoembolization in liver transplantation

Pre-transplant Use of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Multicenter, Retrospective Cohort Study

Systemic Chemotherapy Improves Outcome of Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Downstaging and laparoscopic hepatectomy plus intraoperative radiofrequency ablation for the treatment of initially unresectable multifocal hepatocellular carcinomas

Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study

Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria

Liver-directed combined radiotherapy for downstaging beyond-Milan hepatocellular carcinoma to liver transplantation

Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma

Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review

Downstaging with atezolizumab-bevacizumab: a case series

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation

TKIs treatment for HCC before Liver transplantation: an ELITA/ELTR collaborative study

Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study

Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study

[Electroclinical correlations in 400 cases of photo-cardiozol activations].